Neximmune to present at the h.c. wainwright 24th annual global investment conference

Gaithersburg, md., sept. 09, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced that kristi jones, chief executive officer, will present at the h.c. wainwright 24th annual global investment conference on monday, september 12 at 11:00 am et.
NEXI Ratings Summary
NEXI Quant Ranking